PULSE BIOSCIENCES, INC. — Form 8-K
Filed October 7, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Pulse Biosciences announced completion of enrollment in its NANOPULSE-AF IDE pivotal study on October 7, 2026, with 164 evaluable patients across 15 U.S. clinical sites—three months ahead of the original 9-month timeline. The prospective, non-randomized study evaluates safety and effectiveness of the nPulse Cardiac Catheter System for drug-resistant paroxysmal atrial fibrillation, with primary endpoints assessed at 6 and 12 months post-ablation; pivotal data expected at a future medical conference.
Why this rating
Enrollment milestone de-risks lead cardiac program; 3-month ahead-of-schedule completion and investigator enthusiasm signal strong product-market fit. Material to ~$266M market-cap company pursuing regulatory clearance for significant AF market. Timing now pivots to data presentation and regulatory path.
Tradability signal
NO TRADE
No trade: positive news with only -1.7% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.53% over 4 hrs, n=165). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $49.72 | +10 min · unknown $48.94 ▼ 1.57% | +30 min · unknown $49.43 ▼ 0.59% | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.